SCHEMBL2233308

SCHEMBL2233308

CCN1CCN(C(=O)Cc2ccc(Nc3ncnc4c(C(=O)Nc5c(Cl)c(OC)c(Br)c(OC)c5Cl)csc34)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.42
AURKB Q96GD4 2/20 0.42
PIK3C3 Q8NEB9 1/20 0.41
BRAF P15056 11/20 0.39
RAF1 P04049 7/20 0.39
CSF1R P07333 5/20 0.38
DDR1 Q08345 4/20 0.38
DDR2 Q16832 4/20 0.38
FGFR3 P22607 3/20 0.35
JAK2 O60674 2/20 0.35
ABL1 P00519 2/20 0.35
INSR P06213 2/20 0.35
LCK P06239 2/20 0.35
FYN P06241 2/20 0.35
YES1 P07947 2/20 0.35
LYN P07948 2/20 0.35
RET P07949 2/20 0.35
MET P08581 2/20 0.35
ROS1 P08922 2/20 0.35
KIT P10721 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125151 0.96 AURKA (0.41) AURKAAURKBPIK3C3BRAFRAF1
SCHEMBL14137340 0.92 PIK3C3 (0.44) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL2232895 0.91 PIK3C3 (0.43) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL2232592 0.90 PIK3C3 (0.42) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL2231880 0.90 FGFR3 (0.45) AURKAAURKBPIK3C3BRAFRAF1
SCHEMBL2231261 0.89 PIK3C3 (0.54) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL14125162 0.88 BRAF (0.42) AURKAAURKBBRAFRAF1CSF1R
SCHEMBL14125153 0.88 PIK3C3 (0.42) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL14125149 0.87 PIK3C3 (0.41) PIK3C3BRAFRAF1CSF1RDDR1
SCHEMBL14125150 0.86 PIK3C3 (0.41) PIK3C3BRAFRAF1CSF1RDDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 AURKA 143/4885AURKB 219/4885PIK3C3 312/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 AURKA 143/4885AURKB 219/4885PIK3C3 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.